Assessing the Effectiveness and Safety of Interferon Bladder Infusion for the Treatment of Interstitial Cystitis

Launched by WEST CHINA HOSPITAL · Jun 10, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called interferon bladder infusion for women suffering from interstitial cystitis/bladder pain syndrome (IC/BPS). IC/BPS is a painful condition that causes frequent urination and discomfort in the bladder area. Current treatments can help relieve symptoms, but they don’t target the underlying cause of the condition. Researchers believe that a virus called JC polyomavirus (JCPyV) might play a role in causing IC/BPS, and interferon could help fight this virus. The study aims to see how safe and effective this treatment is for patients.

To participate in the trial, women must be over 18 years old and have been experiencing bladder pain and other urinary symptoms for at least six months. They should also score above a certain level on a specific symptom assessment tool. However, women who are pregnant, have serious health issues, or have had certain recent treatments for their bladder problems are not eligible. If someone qualifies and chooses to participate, they will receive bladder perfusion therapy with interferon and will be monitored for its effects. This trial is not yet recruiting participants, but it could offer a new option for those struggling with IC/BPS in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years old, regardless of gender
• • Combined with bladder pain/discomfort during urination, and at least one lower urinary tract symptom such as frequency and urgency, duration \> 6 months
• • The total score of O'Leary-Sant ICSI+ICPI is more than 18 points
• • Agree to receive bladder perfusion therapy
• Exclusion Criteria:
• • Have a history of allergy to interferon drugs
• • Patients with serious heart, lung, liver, kidney or blood diseases, abnormal liver function, renal insufficiency, etc.
• • Pregnant or lactating women
• • A history of urinary tract infection within 12 weeks
• • IC/ BPS-like symptoms caused by urinary diseases, such as overactive bladder, neurogenic bladder, urinary calculi, radiation cystitis, and endometriosis
• • Within 24 weeks, patients had the following treatment history: bladder hydrodilation, intravesical laser treatment, pelvic floor reconstruction surgery
• • Patients who have taken related drugs or participated in other clinical studies and received study drugs or medical device interventions within 3 months